ABSTRACT
Glycogen storage disease type IV (GSD IV) is an autosomal recessive disorder caused by pathogenic variants in GBE1, resulting in deficient glycogen branching enzyme (GBE) activity and formation of abnormal glycogen (“polyglucosan”). GSD IV manifests across a spectrum of clinical dimensions – including hepatic, neurologic, muscular, and cardiac involvement – which vary in severity. The early-onset forms, historically referred to as Andersen disease, present at different stages ranging from in utero to adolescence. The adult-onset form, referred to as adult polyglucosan body disease (APBD), typically presents in middle to late adulthood. To date, no epidemiological study of GSD IV has been performed. Understanding the global prevalence of GSD IV is critical to increase disease awareness, improve diagnostic rates, inform therapeutic development, and engage pharmaceutical companies. In collaboration with the Rare Genomes Project at the Broad Institute of MIT and Harvard and the APBD Research Foundation, this study curated variants in GBE1 and calculated prevalence across nine genetic ancestry groups. The estimated global carrier frequency of GSD IV is 1 in 243 individuals, and the global genetic prevalence is 1 in 235,784 individuals. Based on the 2024 world population, the estimated number of affected individuals with GSD IV is approximately 34,800. These estimates highlight a significant underdiagnosis of GSD IV and underscore the urgent need for increased awareness of this metabolic disorder. This model of collaboration between researchers, patient advocacy organizations, and genetic data sharing programs provides a framework for estimating the prevalence of other rare diseases in the global population.
Created in BioRender. Koch, R. (2025) https://BioRender.com/j0sg30n.
Competing Interest Statement
Rebecca L. Koch has received grant/funding support from Alnylam Pharmaceuticals. Rebecca L. Koch and H. Orhan Akman have received grant/funding support from the Keith B. Hayes Foundation. Jennifer Orthmann-Murphy is a consultant for Vigil Neuroscience and Savanna Bio as well as a site PI for Vigil Neuroscience clinical trials. Samantha Baxter is a paid consultant for Pharming Group N.V. The Adult Polyglucosan Body Disease Research Foundation is a shareholder of Golden Heart Flower, Ltd., holds a revenue sharing agreement with Columbia University for treatment development of guaiacol, and has received grant/funding support from the Chan Zuckerberg Initiative. All other authors declare no conflict of interest.
Funding Statement
Parts of this study were funded by the Chan Zuckerberg Initiative Donor-Advised Fund at the Silicon Valley Community Foundation 2020-224274 and 2022-316726 (https://doi.org/10.37921/236582yuakxy) (funder DOI 10.13039/100014989).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used openly available human data that were originally located at: ClinVar, the Human Gene Mutation Database (HGMD), and Genome Aggregation Database (gnomAD).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All estimated genetic prevalence reports are publicly available through the Genetic Prevalence Estimator (GeniE) tool. Specifically, the conservative estimates (i.e., only includes pathogenic and likely pathogenic variants in GBE1) are available at https://broad.io/GeniE_GBE1 and the relaxed estimates (i.e., includes pathogenic and likely pathogenic variants as well as variants of uncertain significance in GBE1) are available at https://broad.io/GeniE_GBE1_relaxed.
